Graph AI Secures $13.3 Million Series A to Scale AI Pharmacovigilance Platform Globally

Graph AI, a developer of artificial intelligence platforms focused on pharmaceutical patient safety, has secured $13.3 million in a Series A funding round led by Insight Partners. The financing also included participation from existing investor Bessemer Venture Partners, according to announcements made by the companies. Founded in 2024, the startup intends to deploy the fresh capital to accelerate its commercial expansion across the United States and Europe.

The financing event highlights growing venture capital interest in specialized enterprise automation software designed for heavily regulated life sciences sectors. While the company did not disclose the specific valuation at which the Series A round was raised, the capital injection follows a seed funding round secured in October 2025. The enterprise platform developed by the firm, designated Graph Safety, targets pharmacovigilance operations by combining generative machine intelligence with deterministic controls, validation layers, and end-to-end audit trails.

Pharmacovigilance encompasses the continuous monitoring, collection, assessment, and reporting of adverse drug reactions and safety issues linked to commercialized medicines. Historically, pharmaceutical companies have managed rising case volumes by scaling human headcounts and layered administrative processes over rigid legacy software databases. Graph Safety attempts to modernize these workflows while maintaining strict compliance requirements mandated for drug development and patient safety.

The architecture of the platform emphasizes complete traceability of both system outputs and underlying source data to ensure inspection readiness and support customer validation protocols. According to company disclosures, the software incorporates built-in mechanisms for human oversight, ensuring that safety specialists remain central to final evaluations. Richard Matus, principal at Insight Partners, noted that pharmaceutical firms have traditionally depended on fragmented software suites and disparate service providers for patient safety operations, making integrated workflow automation a key investment rationale for the venture firm.

Since its seed funding round, Graph AI has rolled out two primary functional modules to commercial clients. The intake module automates the initial capture and triage of incoming adverse-event reports streaming from multiple communication channels, while the nucleus module serves as an intelligent safety database that automates case processing through completion. A third module named report, built to handle automated aggregate safety reporting, is scheduled for commercial release.

Operational metrics from live enterprise deployments indicate substantial efficiency gains for participating pharmaceutical and biotechnology customers across North America and other international markets. The platform has reportedly reduced individual case processing turnaround times from upwards of three hours down to less than ten minutes, marking a performance acceleration of more than 90 percent. Additionally, enterprise clients have achieved operational cost reductions of up to 66 percent while deploying the software.

Beyond current commercial offerings, the company is actively developing additional software modules to expand its automated safety ecosystem. A forthcoming product titled signal is currently being designed to proactively surface emerging safety patterns, statistical trends, and early warning signals across aggregated case data. The startup has secured targeted design partnerships with pharma and biotech clients to guide the development of these upcoming capabilities.

Although the company has successfully onboarded enterprise clients across North America and international territories, executives have chosen to withhold the specific names and total count of deployed customers. The strategic focus remains on scaling technical infrastructure and expanding regional sales teams to capture market share among global pharmaceutical enterprises grappling with expanding regulatory reporting burdens.

Industry leaders at Graph AI emphasize that the platform is engineered to augment professional judgment rather than displace clinical experts. The technology absorbs repetitive operational complexity, allowing trained pharmacovigilance specialists to focus analytical resources where clinical expertise is most critical.

"Pharmacovigilance has traditionally scaled against rising case volumes by adding people and processes around legacy systems. We believe intelligence can change that. Graph Safety gives safety experts an intelligent system that takes on operational complexity, while keeping traceability, accountability, and human oversight at the center. We are not replacing human judgment, we are building technology that allows experts to apply it where it matters most," said Raghav Parvataraju, the chief executive officer of the firm.

Graph AI enters its next growth phase with backing from prominent enterprise software investors who have previously supported early-stage deep-tech and AI infrastructure companies. The deployment of the $13.3 million Series A proceeds will center on hiring engineering talent, strengthening regulatory compliance frameworks, and establishing local operational footprints in key international pharmaceutical hubs.

With the upcoming rollout of the automated aggregate reporting module and ongoing development of the signal module, the company aims to solidify its market position. Implementation timelines for the expanded product suite will unfold across North American and European markets over the upcoming fiscal quarters.